Skip to main navigation Skip to search Skip to main content

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

  • Irfan Cicin
  • , Elizabeth R. Plimack
  • , Howard Gurney
  • , Raya Leibowitz
  • , Boris Y. Alekseev
  • , Francis X. Parnis
  • , Avivit Peer
  • , Andrea Necchi
  • , Joaquim Bellmunt
  • , Hiroyuki Nishiyama
  • , Jason Clark
  • , Mihaela Munteanu
  • , Ritesh Kataria
  • , Calvin Jia
  • , Thomas Powles
  • , Cora N. Sternberg
  • Trakya University
  • Macquarie University
  • Sheba Medical Center at Tel Hashomer
  • Tel Aviv University
  • Russian Ministry of Health
  • University of Adelaide
  • Rambam Health Care Campus
  • Fondazione IRCCS Istituto Nazionale dei Tumori
  • Harvard University
  • University of Tsukuba
  • Incyte
  • Merck & Co.
  • Queen Mary University of London
  • Cornell University

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study'. Together they form a unique fingerprint.
Sort by

Neuroscience